Applying Long-Term Survival Evidence in Maintenance Therapy Decisions

This segment explores how long-term survival data and real-world experience inform decisions about maintenance immunotherapy in advanced urothelial (bladder) cancer. The discussion emphasizes that pivotal first-line maintenance trials now have more than five years of follow-up, reinforcing a meaningful overall survival benefit. These data frame conversations around patient life goals, such as reaching key family milestones, and how maintenance therapy can help align treatment with what matters most to each individual.

The speakers compare patients’ typical experience on platinum chemotherapy with that on immune checkpoint inhibitors, noting that although immunotherapy is not free of toxicity, many patients find it more tolerable and compatible with daily life. They also address the difficult question of treatment duration, when, if ever, to stop immunotherapy in patients doing well without side effects, stressing that this remains highly individualized. Finally, the segment highlights how real-world data help extend clinical trial findings to patients who would not have met strict eligibility criteria.